Pharmacokinetics of Meropenem Single Dose Intravenous in Healthy Volunteers

赵彩芸,李家泰,张莉,张朴,刘燕

DOI: https://doi.org/10.3969/j.issn.1001-6821.2004.03.008

2004-01-01

Abstract:Objective To study the pharmacokinetics of single dose of meropenem injection in healthy volunteers. Methods Ten healthy volunteers were selected to receive a single dose of meropenem 500,1000 mg within 30min infusion in an open randomized crossover study. Blood samples were taken for detecting serum concentration before dosing and at 0.25,0.5,0.75,1,1.5,2,3,4,5,6,8 h after completion of the intravenous infusion. The urine samples were collected at time periods of 0 to 2, 2 to 6, 6 to 12 and 12 to 24 h after the end of infusion. The concentrations of meropenem in serum and urine were determined by a high-pressure liquid chromatography (HPLC) method. Results Pharmacokinetic profiles were conformed to an open two-compartment model analyzed by using 3P97 and the results of HPLC method were as follows: the Cmax of 500, 1000mg meropenem at the end of infusion were 23.08 ±4.00,48.19 ±9.78 mg·L-1; the AUC were27.47 ±3.80,55.56 ± 6.72 mg·L-1; the t1/2β were 1.08± 0.19,1.15±0.15 h; the CL were 18.91±2.48,18.68± 2.32 L·h-1; the Vd were 13.48 ±2.94,13.93±2.40L; respectively. Urinary recovery rates were (60.11±5.20)% and (61.23 ±9.81)% of two doses in 12 h, respectively. Conclusion Meropenem was well tolerance in single dose infusion in healthy Chinese volunteers. The pharmacokinetics of the drug in trial dose nearly fit linear dynamic feature, and the drug maily excreted through kidney.